SM
VTVT icon

Sabby Management’s vTv Therapeutics VTVT Stock Holding History

Sabby Management’s Portfolio VTVT Stock Details VTVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-5,579
Closed -$382K – 109
2019
Q1 		$382K Buy
+5,579
New +$541K 0.18% 40
2018
Q1 		– Sell
-1,113
Closed -$267K – 183
2017
Q4 		$267K Sell
1,113
-409
-27% -$91.7K 0.02% 118
2017
Q3 		$364K Sell
1,522
-1,413
-48% -$282K 0.02% 111
2017
Q2 		$583K Sell
2,935
-160
-5% -$33.4K 0.04% 130
2017
Q1 		$811K Sell
3,095
-219
-7% -$49.9K 0.04% 143
2016
Q4 		$640K Sell
3,314
-55
-2% -$12.6K 0.04% 180
2016
Q3 		$969K Sell
3,369
-125
-4% -$30.1K 0.04% 188
2016
Q2 		$811K Hold
3,494
– – 0.04% 176
2016
Q1 		$721K Hold
3,494
– – 0.04% 185
2015
Q4 		$952K Sell
3,494
-520
-13% -$146K 0.05% 191
2015
Q3 		$1.05M Buy
+4,014
New +$1.4M 0.04% 227

Other funds holding VTVT

Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Sabby Management's VTVT Position: Q2 2019 in Review

Sabby Management sold out of vTv Therapeutics (VTVT) in Q2 2019, closing a stake of 5,579 shares — an estimated $382K sold.

Sabby Management first reported a position in VTVT in Q3 2015 and held it in 11 quarters. The position peaked at $1.05M in Q3 2015. 20 funds tracked by Wall St. Rank hold VTVT as of Q2 2019.

  • Sabby Management reported no remaining vTv Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Sabby Management sold 5,579 vTv Therapeutics shares in Q2 2019, an estimated $382K.
  • Sabby Management first reported a position in vTv Therapeutics in Q3 2015 and held it in 11 quarters.
  • Sabby Management's vTv Therapeutics position peaked at $1.05M in Q3 2015.
  • 20 funds tracked by Wall St. Rank held vTv Therapeutics as of Q2 2019.

Based on Sabby Management's 13F filing for Q2 2019, filed 14 Aug 2019.